The Immune System Answer to Cancer
For every patient whose cancer responds to today’s checkpoint therapies, many more do not.
OX2 Therapeutics’ goal with peptide immunotherapy is to reactivate the immune system so effective anti-tumor response becomes the rule, not the exception.
The OX2 Therapeutics Pipeline
Our therapeutic pipeline is advancing across multiple solid tumor cancers.
Clinical Trial Participation: Keeping Patients Front and Center
We aim to deliver new immunology approaches that increase therapeutic benefit, lessen side effects and extend the length and quality of life for patients with devastating cancer that currently have no cure.
Only with the help of participants in our studies can we have the potential to offer new, potentially curative treatments for patients in need.
"We are thrilled to report that patients treated in the trial have had no significant side-effects. They have been thriving and living life to the fullest, and they have hope that this trial might help improve their outcome and that by participating in this trial they are helping future patients."
– Dr. Anne Bendel, Pediatric Oncologist, Children's Minnesota
"Access to a new investigational therapy meant a chance to fight back when standard options were limited."
– Trial Participant
"We know innovation depends on patients willing to participate. Every step forward brings future families more options and more time."